Company intelligence / Profile preview

Nectar Life Sciences

New York City, New York, United Statesnectarlifesciences.com ↗

Ownership: Private
Development stage: Commercial

Overview

Clinical survey data shows most patients report improvement in symptoms within months of starting personalized sublingual immunotherapy. The company has rapidly grown its test sales and expanded into brick-and-mortar clinics.

Therapeutic areas: Immunology
Modalities: Sublingual immunotherapy drops ("Allergy Drops")Small molecule (allergen extracts)Device (at-home testing kit)
Industry: Biotech

Drug pipeline

1 asset

Nectar Allergy Drops

Preclinical

Partnerships

Juxtapose and Obvious Ventures are co-building partners/investors.MedInd Group provides C-suite services for clinic operations.

Beyond the preview

Go deeper on Nectar Life Sciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nectar Life Sciences.